Navigation Links
Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
Date:2/5/2008

in the value of the make-whole provision of our convertible notes and CEO transition expenses, as adjusted by the amount of additional taxes payable or tax benefit that the company would accrue if it used non-GAAP results instead of GAAP results to calculate the company's tax liability.

Non-GAAP EPS is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis.

Non-GAAP gross profit and gross margin consists of GAAP gross profit and gross margin excluding share-based compensation expense under SFAS No 123R.

Non-GAAP operating expenses consists of GAAP operating expenses excluding share-based compensation expense under SFAS No. 123R, amortization of purchased intangibles, settled securities litigation and CEO transition expenses.

Non-GAAP income from operations consists of GAAP income from operations excluding share-based compensation expense under SFAS No. 123R and amortization of purchased intangibles.

Non-GAAP tax rate consists of the GAAP tax rate adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec's operations to exclude amortization of intangibles, and in-process research and development expenses. These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events. Management also believes that it is useful to exclude settled securities litigation and CEO transition expenses because these expenses occur infrequently and therefore are not relevant to an understanding of our core operating performance. Management believes it is useful to exclude the value of the make-whole provision of our convertible notes as this item is also not indicative of Thoratec's core operating business. The make-whole provision is a non-operating item that is included in other income (expens
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Thoratec Presentation at JP Morgan Conference to be Webcast
2. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
3. Thoratec Presentation at Bear Stearns Conference To Be Webcast
4. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
9. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Shenzhen ... – Beike Biotechnology, the world,s largest stem ... derived mesenchymal stem cell packets containing no less ... new product could significantly reduce the time and ... in the case of degenerative conditions such ...
(Date:5/6/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. ... cancers, today announced that Linda Powers , NW Bio CEO, ... vaccine platform for solid tumor cancers and the Company,s multiple ...   , , , DATE: , , , ... , , , 12:15 PM EDT , , , ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research Officer from ... the 2015 Asian Starch Conference, to be held ... , As an honored ... Starch: A Potential Source for the Creation of Next ... a 528 page text book entitled "Advances in Potato ...
(Date:5/5/2015)... 5, 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens,  today announced that ... of America Merrill Lynch 2015 Health Care Conference on May ... Encore at the Wynn, Las Vegas NV. ... will be available through the investor relations section of Roka ...
Breaking Biology Technology:Beike Biotechnology Produces High-dose Adult Stem Cell Packets for Degenerative Conditions 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2
... Traits to Improve Farmer ... ... Biotechnology Co., Ltd. (BWK) today announced the,formation of a joint venture ... as stress tolerance and efficient nutrient,utilization to improve the performance of ...
... December 10, 2007, SPACE COAST, Fla., Dec. ... Third Annual Colloquium on the Law of,Transbeman Persons, ... held December 10, 2007 along Florida,s Space Coast. ... and computerized,substrate., The colloquia are open to ...
... and GAITHERSBURG, Md., Nov. 30 Binex,(KOSDAQ: 053030) ... a,Sponsored Research Agreement to evaluate MaxCyte,s GMP-compliant cell,loading ... cancer immunotherapies. Upon completion of the research studies,the ... technology for,clinical and commercial use in Korea. Financial ...
Cached Biology Technology:DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 2DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 3International Human Rights Day Recognized by Terasem Movement, Inc.'s Third Annual Colloquium on the Law of Transbeman Persons 2Binex and MaxCyte Collaborate on Cancer Immunotherapy Research 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... chairman of Singapore A*STAR,s Biomedical Research Council, has received ... cancer research through his discovery of p53 tumour suppressor ... one of the highest accolades from the Royal Society ... endeavour have made an impact on people,s lives worldwide. ...
... ionising radiation with ever better methods sci-entists have ... age. In addition to natural radiation, mankind is exposed ... result from the military and technical use of radioactive ... medical applications, it is necessary to determine even the ...
... Sept. 16, 2008 Researchers at UT ... improve electrical stimulation of nerves by outfitting electrodes ... coating of basic black, formed from carbon nanotubes. ... and transmitted by electrodes, which researchers say is ...
Cached Biology News:Radioactivity: Discover the lowest amounts with new methods 2Radioactivity: Discover the lowest amounts with new methods 3Coating improves electrical stimulation therapy used for Parkinson's, depression, chronic pain 2
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... serum is collected off the clot from fasted Cynomolgus ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA ... N-07: CPD N-09: K3EDTA ...
adult...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: